Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

Psychopharmacology

Volumn 146, Issue 1, 1999, Pages 81-86

  Gründer, Gerhard ^a   Müller, Matthias J ^a   Andreas, Jörg ^a   Heydari, Nilufar ^a   Wetzel, Hermann ^a   Schlösser, Ralf ^a   Schlegel, Sabine ^a   Nickel, Otmar ^a   Eissner, Dagmar ^a   Benkert, Otto ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antipsychotic; Dopamine receptor; EMD 57445; Iodobenzamide; Sigma receptor; Single photon emission computed tomography

Indexed keywords

BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DRUG METABOLITE; EMD 59983; IODINE 125; NEUROLEPTIC AGENT; PANAMESINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BLOOD-BRAIN BARRIER; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLES; PIPERIDINES; PYRIMIDINES; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032826204     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051091     Document Type: Article

References (42)

1. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672
2. Bartoszyk GD, Bender HM, Hellmann J, Schnorr C, Seyfried CA (1996) EMD 57445: a selective sigma receptor ligand with the profile of an atypical neuroleptic. CNS Drug Rev 2:175-194
3. 2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11:220-228
4. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 117:55-61
5. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) The extrapyramidal symptom rating scale. Can J Neurol Sci 7:233
6. Dahmen N, Fischer V, Hodl P, Rujescu D, Reuss S, Bartoszyk GD, Hiemke C (1996) Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. Eur Neuropsychopharmacol 6:237-243
7. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
8. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
9. Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A (1997) Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 132:82-88
10. 2 receptor blockade in schizophrenia. Biol Psychiatry 32:293-295
11. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994) BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40
12. Gudelsky GA, Nash JF (1992) Neuroendocrinological and neurochemical effects of sigma ligands. Neuropharmacology 31: 157-162
13. Guitart X, Ballarin M, Carceller A, Codony X, Dordal A, Hernandez E, Laloya M, Perez R, Ruiz MT, Farre AJ (1997) Pharmacological profile of E-5842, a sigma receptor ligand with atypical antipsychotic activity in animal models. Soc Neurosci Abstr 23:530
14. Guy W (1976) Clinical global impressions CGI. In: Guy W (ed) ECDEU assessment manual for psychopharmacology, revised. Rockville, Maryland
15. Haertzen CA (1970) Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI). Psychopharmacologia 18:366-377
16. Itzhak Y, Alerhand S (1989) Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice. FASEB J 3:1868-1872
17. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
18. Kay SR, Opler LA, Fiszbein A (1992) The positive and negative syndrome scale (PANSS), rating manual. Multi Health Systems, Toronto
19. 2 receptor occupancy levels. Psychiatry Res 75:91-101
20. 123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 30:88-92
21. Largent BL, Wikström H, Snowman AM, Snyder SH (1988) Novel antipsychotic drugs share high affinity for sigma receptors. Eur J Pharmacol 155:345-347
22. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240
23. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-74
24. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 334: 1-100
25. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
26. Matsuno K, Matsunaga KH, Mita S (1995) Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum. Neurochem Res 20:233-238
27. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235
28. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L (1998) Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13:S15-20
29. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Reports 10:799-812
30. Patrick SL, Walker JM, Perkel JM, Lockwood M, Patrick RL (1993) Increases in rat striatal extracellular dopamine and vacuous chewing produced by two sigma receptor ligands. Eur J Pharmacol 231:243-249
31. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16-26
32. 2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology 124:285-287
33. 123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. J Neural Transm 99:173-185
34. 123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. Psychiatry Res 75:103-114
35. Shibuya H, Mori H, Toru M (1992) Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 17:983-990
36. Simpson MD, Slater P, Royston MC, Deakin JF (1991) Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6:41-48
37. Sorenson JA (1974) Quantitative measurement of radioactivity in vivo by whole-body counting. In: Hine, GJ, Sorenson JA (eds) Instrumentation in nuclear medicine. Academic Press, New York, pp 248-311
38. 123I-IBZM using the rotating gamma camera. Nucl Med Commun 12:687-697
39. 2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 34: 2076-2084
40. Wachtel SR, White FJ (1988) Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. J Pharmacol Exp Ther 244:410-416
41. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB (1991) Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 29:41-54
42. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908